A phase IIb, randomised, double-blind, placebo-controlled, dose-ranging investigation of the safety and efficacy of NTCELL® [immunoprotected (alginate-encapsulated) porcine choroid plexus cells for xenotransplantation] in patients with Parkinson's disease

Publication | Closed Access

DOI

Citations

References

2018

Year

Barry Snow, Eoin Mulroy, Arnold Bok, M. P. Simpson, A. J. Smith, Kenneth M. Taylor, Michelle Lockhart, BB Janice Lam, Christopher Frampton, Patrick Schweder,

Parkinsonism & Related Disorders

Regenerative MedicineCell TherapyXenotransplantationMedicineImmunologyTherapeutic EfficacyPhase IibExperimental TherapeuticDose-ranging InvestigationImmunotherapyPharmacology